ATE268382T1 - MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2 - Google Patents

MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2

Info

Publication number
ATE268382T1
ATE268382T1 AT98105047T AT98105047T ATE268382T1 AT E268382 T1 ATE268382 T1 AT E268382T1 AT 98105047 T AT98105047 T AT 98105047T AT 98105047 T AT98105047 T AT 98105047T AT E268382 T1 ATE268382 T1 AT E268382T1
Authority
AT
Austria
Prior art keywords
cdr
seq
human
chain
ßcdr
Prior art date
Application number
AT98105047T
Other languages
English (en)
Inventor
Nakamura Kazuyasu
Hanai Nobuo
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE268382T1 publication Critical patent/ATE268382T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98105047T 1997-03-19 1998-03-19 MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2 ATE268382T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP06698197A JP4550947B2 (ja) 1997-03-19 1997-03-19 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体

Publications (1)

Publication Number Publication Date
ATE268382T1 true ATE268382T1 (de) 2004-06-15

Family

ID=13331716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98105047T ATE268382T1 (de) 1997-03-19 1998-03-19 MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2

Country Status (7)

Country Link
EP (1) EP0882794B1 (de)
JP (1) JP4550947B2 (de)
AT (1) ATE268382T1 (de)
AU (1) AU751948B2 (de)
CA (1) CA2226400C (de)
DE (1) DE69824234T2 (de)
ES (1) ES2219802T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407734B1 (en) 1994-10-31 2002-06-18 Nec-Mitsubishi Electric Visual Systems Corporation Power supply system capable of reducing power consumption during interruption of an external input signal given to an operating circuit
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
WO2001023431A1 (fr) * 1999-09-30 2001-04-05 Kyowa Hakko Kogyo Co., Ltd. Derives d'anticorps contre le ganglioside gm2
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2016204535C1 (en) * 2000-04-12 2017-02-23 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anti-D monoclonal antibodies
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP3263702A1 (de) * 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Zellen, die antikörperzusammensetzungen herstellen
ES2303859T3 (es) * 2001-06-28 2008-09-01 Kyowa Hakko Kogyo Co., Ltd Anticuerpo humanizado contra el factor de crecimiento fibroblastico 8 y fragmento del anticuerpo.
WO2003049704A2 (en) 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
EP1466623B1 (de) * 2001-12-28 2009-04-22 Kyowa Hakko Kogyo Co., Ltd. Anti-fgf-8 antikörper gegen arthritis
EP1500400A4 (de) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Arzneimittel mit antikörper-zusammensetzung
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
CA2548787A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Antibody composition specifically binding to ganglioside gm2
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2008090960A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
JP6310397B2 (ja) * 2012-12-06 2018-04-11 国立大学法人金沢大学 中皮腫の治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598998B1 (de) * 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanisierte Antikörper, die mit dem GM2-Gangliosid reagieren

Also Published As

Publication number Publication date
CA2226400C (en) 2008-12-02
ES2219802T3 (es) 2004-12-01
EP0882794B1 (de) 2004-06-02
DE69824234D1 (de) 2004-07-08
AU751948B2 (en) 2002-09-05
AU5942098A (en) 1998-10-01
CA2226400A1 (en) 1998-09-19
DE69824234T2 (de) 2005-06-23
EP0882794A3 (de) 1999-06-16
EP0882794A2 (de) 1998-12-09
JPH10257893A (ja) 1998-09-29
JP4550947B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
ATE268382T1 (de) MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2
FR12C0004I1 (de)
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
TR200200735T2 (tr) CTLA-4 için insan monoklonal antikorları
JP2004527212A5 (de)
GEP20105118B (en) Anti-vegf antibodies
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NZ331014A (en) Anticoagulant agents useful in treatment of thrombosis
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
ATE373712T1 (de) Natürlicher menschlicher antikörper
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
EP2308894A3 (de) Humanisierte Anti-NGF-Antikörper
CA2294078A1 (fr) Procede de dosage specifique du c-peptide
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
FR2781481B1 (fr) Nouveaux 2-amino, 4-alkylamino pyrimidine 3-oxydes et composition les comprenant
CA2361987A1 (en) Goodpasture antigen binding protein
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
AU4876196A (en) A process for the preparation of factor ix from biological sources
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
AU5569600A (en) Novel protein and dna thereof
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
IT1291419B1 (it) Gruppo illuminante per l'illuminazione di acquari,terrari e simili.
EP1702984A3 (de) Verfahren zum Nachweis von Prostatakrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties